sec filing
MY
NASDAQ · MYNZ
Mainz Biomed B.V.
Healthcare · Medical - Diagnostics & Research
$0.84
Up+$0.03 (+0.84%)
Updated Sep 16, 2026, 11:08 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.3M
- P/E ratio
- -0.05
- Dividend yield
- 0.00%
- 52-week range
- $0.74 – $0.87
- Volume
- 5.25M
- Avg. volume
- 494.63K
Price performance
MYNZ price history
1M range · 0 trading sessions · Daily adjusted prices
MYNZ does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest MYNZ news
The latest Smart Investors Daily articles mentioning MYNZ.
Stock researchCompany · Overview
MYNZ research
Overview
Company profile and research snapshot.
Company profile
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 14, 2025 | Maxim Group | Buy | — |
| Nov 25, 2024 | HC Wainwright & Co. | Neutral | — |
| Apr 12, 2024 | Cantor Fitzgerald | Neutral | — |
| Mar 6, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 21, 2023 | Cantor Fitzgerald | Neutral | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.